转移性肾癌免疫治疗研究进展

The research progression of immunotherapy for metastatic renal cell carcinoma

转移性肾癌对传统放、化疗均不敏感，目前尚缺乏有效的治疗手段。IL-2和IFN-α是目前研究较多的细胞因子制剂，但单独应用于转移性肾癌患者的治疗时效率低。近年来，随着分子免疫机制的研究进展，疫苗、过继免疫治疗的研究发展迅速，特别是树突状细胞疫苗（DC vaccine）和自体细胞因子诱导的杀伤细胞（CIK）的研究取得了很大的进展。

Metastatic renal cell carcinoma （RCC） usually resistants to traditional chemotherapy and radiotherapy. Interleukin-2 and interferon-otare the common significant cytokines studied extensively. However the clinical efficacy is not desirable when interleukin-2 or interferon-cds used alone. With the development of molecular immunology, studies on vaccines and autologous cytokine induced killer Cells progress quickly. This review summarizes the research progression of immunotherapy for metastatic renal cell carcinoma.